The IMI-2 Call for Innovative Medicines Initiative IMI-2 is open

5 de February de 2020

The call gives researchers from various sectors the opportunity to participate in ambitious public-private partnerships for the development of future medicines.

IMI2 – Call 20 was launched on January 21, 2020 and is a call for standard two-stage proposals.

Why request?

– Obtain funds for research.

– Participate in a scientifically excellent patient-centered investigation

– Join unique consortia that involve the best teams in the industry, academia, SMEs, regulators and others.

– It means benefiting from the experience, databases and infrastructure of the consortium partners.

– Increase the visibility and status of your organization in Europe and worldwide and access to new markets.


– Early diagnosis, prediction of radiographic results and development of rational and personalized treatment strategies to improve long-term results in psoriatic arthritis.

– Innovations to accelerate the development and manufacture of vaccines.

– Academy merger in innovation and treatment for tuberculosis (UNITE4TB).

– Tumor plasticity.

– Proton versus photon therapy for esophageal cancer – trimodality strategy.

– Management of protein pharmacological products and stability problems.

More information on the topics:

Deadline for short proposals: April 21, 2020


Visit the IMI website:

For more information about the call you can contact